Related Experiment Video
Updated: Jun 16, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Rivaroxaban: a new oral factor Xa inhibitor
Elisabeth Perzborn1, Susanne Roehrig, Alexander Straub
1Cardiovascular Pharmacology, Pharma R&D Discovery Research, Bayer Schering Pharma AG, Aprather Weg 18a, D-42096 Wuppertal, Germany. elisabeth.perzborn@bayerhealthcare.com
Arteriosclerosis, Thrombosis, and Vascular Biology
|February 9, 2010
Summary
Rivaroxaban, a direct factor Xa inhibitor, effectively prevents blood clots by reducing thrombin generation. Clinical trials show it reduces venous thromboembolism after surgery with a favorable safety profile compared to enoxaparin.
Area of Science:
- Pharmacology and Toxicology
- Hematology
- Cardiovascular Medicine
Background:
- Factor Xa is a critical enzyme in the coagulation cascade, essential for thrombin generation and clot formation.
- Direct factor Xa inhibitors offer targeted anticoagulation with potential for predictable pharmacokinetics.
- Venous thromboembolism (VTE) remains a significant complication following major orthopedic surgery.
Purpose of the Study:
- To evaluate the efficacy and safety of rivaroxaban as a direct factor Xa inhibitor.
- To assess the antithrombotic activity of rivaroxaban in preclinical models and human subjects.
- To compare rivaroxaban with enoxaparin for VTE prevention in patients undergoing hip or knee arthroplasty.
Main Methods:
- In vitro characterization of rivaroxaban's inhibition of factor Xa, including selectivity and binding kinetics.
- Assessment of antithrombotic effects in animal models of venous and arterial thrombosis.
- Pharmacokinetic and pharmacodynamic studies in healthy individuals.
- Phase III clinical trials comparing rivaroxaban regimens to enoxaparin regimens for VTE prophylaxis post-arthroplasty.
Main Results:
- Rivaroxaban demonstrated high selectivity for human factor Xa (>10,000-fold) and potent, concentration-dependent inhibition (Ki = 0.4 nmol/L).
- The drug inhibited both free and complex-bound factor Xa, reducing thrombin generation.
- Animal studies showed dose-dependent antithrombotic activity.
- In healthy subjects, rivaroxaban exhibited predictable pharmacokinetics and pharmacodynamics.
- Phase III trials revealed rivaroxaban significantly reduced VTE rates compared to enoxaparin post-arthroplasty, with comparable major bleeding rates.
Conclusions:
- Rivaroxaban is a potent and selective direct factor Xa inhibitor with significant antithrombotic activity.
- The drug shows predictable pharmacokinetic and pharmacodynamic properties.
- Rivaroxaban offers a favorable benefit-to-risk profile for VTE prevention in patients following hip or knee arthroplasty.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...